JASON EHRLICH - 21 Jun 2021 Form 4 Insider Report for Kodiak Sciences Inc. (KOD)

Role
Chief Medical Officer and Chief Development Officer
Signature
/s/ David Peinsipp, Attorney-in-Fact for Jason Ehrlich
Issuer symbol
KOD
Transactions as of
21 Jun 2021
Net transactions value
-$590,085
Form type
4
Filing time
23 Jun 2021, 17:38:11 UTC
Previous filing
17 Jun 2021
Next filing
22 Jul 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KOD Common Stock Sale $39,053 -475 -0.71% $82.22* 66,658 21 Jun 2021 Direct F1, F2
transaction KOD Common Stock Sale $32,274 -387 -0.58% $83.39* 66,271 21 Jun 2021 Direct F1, F3
transaction KOD Common Stock Sale $158,999 -1,884 -2.8% $84.39* 64,387 21 Jun 2021 Direct F1, F4
transaction KOD Common Stock Sale $287,030 -3,359 -5.2% $85.45* 61,028 21 Jun 2021 Direct F1, F5
transaction KOD Common Stock Sale $72,729 -845 -1.4% $86.07* 60,183 21 Jun 2021 Direct F1, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan.
F2 The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $81.615 to $82.605, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in these footnotes.
F3 The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $82.735 to $83.66, inclusive.
F4 The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $83.82 to $84.765, inclusive.
F5 The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $84.85 to $85.77, inclusive.
F6 The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $85.895 to $86.16, inclusive.

Remarks:

Chief Medical Officer and Chief Development Officer